Trial Profile

A phase 1/2 adaptive-design study assessing LNS-8801 in combination with pembrolizumab in patients with advanced solid tumors who had previously responded to anti-PD-1 therapy and have since progressed.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jun 2022 According to a Linnaeus Therapeutics media release, company Announces Presentation of Positive Clinical Data of LNS8801 at 2022 ASCO Annual Meeting
06 Jun 2022 Results published in the Linnaeus Therapeutics Media Release
13 Oct 2020 Status changed from planning to recruiting, according to a Linnaeus Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com